During drug development, companies may utilize a variety of labeling-related tools that employ target labeling to facilitate drug development, while simultaneously aligning desired marketing and labeling objectives with the development program design or study design and drafting clinical overview (CO). Some of the clinical labeling tools utilized during drug development are:

  • Investigator Brochure (IB)
  • Target Labeling (TL)/ Target Profile
  • Development Core Data Sheet (DCDS)
  • Development Core Safety Information (DCSI)
  • FDA Target Product Profile (TPP)

It is very important for companies to employ a modular approach while collecting the evolving safety and efficacy information across various types of clinical labels. This would satisfy the need to help investigators and sponsors more effectively by presenting and updating a focused, dedicated DCSI section that can conveniently be placed under these different clinical categories. Furthermore, DCSI develops into the CCSI that is included in the first Company Core Data Sheet (CCDS) and is utilized for the product's entry into the market. Drafting a thoroughly versed clinical overview (CO) comprising of scope and the critical issues in the clinical developmental programme pertaining to the drug is also required to support the documentation for the assessors.

Clinical Overview and Labeling Process

To navigate organizations through Regulatory requirements, Freyr offers specialized clinical labeling services.   


Freyr Expertise

Creation and review of Investigational brochure (IB)

Freyr has considerable expertise in the creation, authoring and review of IBs for various clinical stage programs of our clients.  IBs are the most nascent forms of labels, intended to provide the investigator or treating physician with information regarding the drug/intervention. Their purpose is toprovide the investigators and others involved in the trial with the information required to facilitate their understanding of the rationale for, and their compliance with, many key features of the protocol, such as the dose, dose frequency/interval, methods of administration and safety monitoring procedures. The IB contains pre-clinical and clinical information related to an investigational drug.

While working on IBs, Freyr labeling experts present the information in a concise, simple, objective and balanced form. The same qualities can be considered when translating documents as well. In addition to authoring IBs, Freyr also supports the annual review of IBs and works on revisions, as necessary, in compliance with standard procedures established by clients and sponsors.  

Development of Target Labeling (TL)/ Target Profile

Development and review of DCDS & DCS

Freyr has proven expertise in creating high quality Developmental Core Data Sheets (DCDS). The DCDS is an intermediary core label which plays an important role in deriving content for first- to- file national labels (like USPI, SmPC etc). The DCDS/DCSI is prepared from the target label, and it provides integrated safety and efficacy to an intervention or drug.  The DCDS/DCSI helps investigators and sponsors more effectively by presenting and updating focused, dedicated DCDS sections that can conveniently be placed within the IB. The DCSI help in developing Company Core Safety Information (CCSI), which later forms an integral part of the Company Core Data Sheet (CCDS).

Development and review of FDA Target Product Profile (TPP), EU-draft SmPC (dSmPC)

  Target Product Profile (TPP)/draft Summary Product Characteristics (dSmPC) are a form of clinical labels that facilitate the discussions between Pharmaceutical companies and the Health Authorities. The TPP/dSmPc are used throughout the drug development process, from pre-investigational new drug application (pre-IND) or investigational new drug application (IND) phases of drug development through post marketing programs to pursue new indications or other substantial changes in clinical labeling. Pharmaceutical companies specify the labeling concepts that are the goals of the drug development program in the form of TPP/dSmPC. Ideally, TPP/dSmPC provides a statement of the overall intent of the drug development program and gives information about the drug at a particular phase of development. As a strategic Regulatory partner, Freyr has expertise in preparing Target Product Profiles for the US, and dSmPc for the EU. 


Freyr Advantages

  • Resources with in-depth Regulatory knowledge in clinical packaging and labeling
  • Expertise in successfully handling global and regional drug labeling for Fortune Pharma clients across the globe; USA, EUROPE, APAC, MENA etc.
  • Global Regulatory expertise in covering life sciences organizations viz. Pharma, Biotech, and Nutrition manufacturers
  • Highly qualified medical writers possessing extensive Regulatory Labeling experience
  • In-depth and updated understanding of the global drug labeling changes from multiple Health Authorities such as: USFDA, EMA, TGA etc.
  • Dedicated compliance team tracking the status of core and company core data sheet (CDS / CCDS) implementation in regional labels
  • Highly experienced Pharmaceutical, Biotech and Nutrition labeling professionals


To streamline end-to-end Regulatory labeling practice from creation to tracking to managing in company of any size, Freyr offers a centralized labeling life cycle management software, Freyr LABEL. Right from creating, tracking and managing company core data sheet (CCDS) deviations, CCDS updates, and developments to creating, implementing, and inspecting multi-lingual regional labels as well as custom reporting. Freyr LABEL puts companies in total control of all their Regulatory labeling compliance needs.

Would you like to decode complete information and gain a first-hand experience of Freyr LABEL?